[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606088":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":25,"locations":34,"responsibleParty":52,"collaborators":11,"id":54,"slug":11,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":11,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-8068，adebelizumab and platinum-based chemotherapy","EXPERIMENTAL",null,[13],"Drug: SHR-8068，adebelizumab and platinum-based chemotherapy",{"label":15,"type":16,"description":11,"interventionNames":17},"tislelizumab, and platinum-based chemotherapy","ACTIVE_COMPARATOR",[18],"Drug: tislelizumab, and platinum-based chemotherapy",[20,23],{"type":21,"name":9,"description":9,"armGroupLabels":22,"otherNames":11},"DRUG",[9],{"type":21,"name":15,"description":15,"armGroupLabels":24,"otherNames":11},[15],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Weixia Li","CONTACT","+86 021-61053363","weixia.li@hengrui.com",{"name":32,"role":28,"phone":29,"phoneExt":11,"email":33},"Yang Wang","yang.wang.yw263@hengrui.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Affiliated Cancer Hospital of Shandong First Medical University","RECRUITING","Jinan","Shandong","250117","China",{"type":43,"coordinates":44},"Point",[45,46],116.99722,36.66833,{"lat":46,"lon":45},[49],{"name":50,"role":51,"phone":11,"phoneExt":11,"email":11},"Jinming Yu","PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606088",false,"NCT07170995","Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","A Randomized, Open-label, Controlled, Multicenter Phase III Study of SHR-8068 Combined With Adebrelimab and Platinum-based Chemotherapy Versus Tislelizumab Combined With Platinum-based Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Voluntary participation and written informed consent.\n2. 18-75 years old, no gender limitation.\n3. Newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation.\n4. Confirmed tumor PD-L1 status prior to randomization.\n5. Eastern Cooperative Oncology Group (ECOG) score: 0-1\n6. With a life expectancy ≥ 3 months.\n7. At least one measurable lesion according to RECIST v1.1.\n\nExclusion Criteria:\n\n1. Have untreated central nervous system metastasis; or have meningeal metastasis or spinal cord compression;\n2. Uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites;\n3. Previous or co-existing malignancies；\n4. Have Active or prior documented autoimmune or inflammatory disorders;\n5. Active hepatitis B or hepatitis C, or with a history of immunodeficiency;\n6. Have an active or past medical history of interstitial lung disease (ILD)\u002Fpneumonitis, including drug-induced or radiation ILD\u002Fpneumonitis.","ALL","18 Years","75 Years",{"count":64,"type":65},460,"ESTIMATED","INTERVENTIONAL",[68],"PHASE3","This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.",[71],"Advanced or Metastatic Non-small Cell Lung Cancer","2025-11-14",{"date":74,"type":75},"2025-11-18","ACTUAL",{"date":77,"type":75},"2025-10-22",{"date":79,"type":65},"2030-12",{"name":5,"class":6},1]